Company on the CCEL bandwagon
Since there are so few people following Cryo-Cell, I thought it was worth sharing that I just ran across another blog, Casino Capitalism, that has purchased CCEL shares and follows them with some regularity.
According to the latest info he's posted, he bought shares of CCEL at $3.90, which is just about the same as my current cost per share of $3.89, so we must be thinking at least similarly on this one. He expects them to double within the year, which may be a bit ambitious (but I'll happily accept it).
I've written about CCEL several times, I posted an article with my detailed analysis of the company and the stem cell banking trend back in November, then most recently wrote them up about a month ago following their last earnings release.
Casino Capitalism has a few posts on CCEL that I've seen -- this one on his argument for stem cell banking stocks in general last Fall, another on the importance of federal stem cell banking legislation, and another on CCEL's introduction of their Plureon product. Certainly worth checking out for those of you who, like me, have an interest in seeing how the growing popularity of stem cells impacts this solidly run, profitable company.
One thing Casino Capitalism and I certainly agree on is the importance of the possible near-term catalyst of CCEL's relisting on a major exchange -- if they get back on the Nasdaq or onto the AMEX in 2006 as is widely expected I think the company will get a lot more attention and may well be richly rewarded for their very solid and steady ongoing revenue stream as well as their significant growth prospects as stem cell banking enters the mainstream.
Glad to see someone else on the CCEL bandwagon -- I'll be looking forward to seeing how the plureon product sells, and how well CCEL holds up against the swelling ranks of competitors, but I really think the cord blood banking business will be a rising tide that lifts nearly all the boats -- and certainly CCEL, one of the oldest, largest, and best financed companies in the business should grow at least as quickly as the overall industry.
According to the latest info he's posted, he bought shares of CCEL at $3.90, which is just about the same as my current cost per share of $3.89, so we must be thinking at least similarly on this one. He expects them to double within the year, which may be a bit ambitious (but I'll happily accept it).
I've written about CCEL several times, I posted an article with my detailed analysis of the company and the stem cell banking trend back in November, then most recently wrote them up about a month ago following their last earnings release.
Casino Capitalism has a few posts on CCEL that I've seen -- this one on his argument for stem cell banking stocks in general last Fall, another on the importance of federal stem cell banking legislation, and another on CCEL's introduction of their Plureon product. Certainly worth checking out for those of you who, like me, have an interest in seeing how the growing popularity of stem cells impacts this solidly run, profitable company.
One thing Casino Capitalism and I certainly agree on is the importance of the possible near-term catalyst of CCEL's relisting on a major exchange -- if they get back on the Nasdaq or onto the AMEX in 2006 as is widely expected I think the company will get a lot more attention and may well be richly rewarded for their very solid and steady ongoing revenue stream as well as their significant growth prospects as stem cell banking enters the mainstream.
Glad to see someone else on the CCEL bandwagon -- I'll be looking forward to seeing how the plureon product sells, and how well CCEL holds up against the swelling ranks of competitors, but I really think the cord blood banking business will be a rising tide that lifts nearly all the boats -- and certainly CCEL, one of the oldest, largest, and best financed companies in the business should grow at least as quickly as the overall industry.
Labels: CCEL








